Posted 29 September, 2023

Adlai Nortye Ltd. IPO completed

IPO completed detected for ticker Nasdaq:ANL in a 424B4 filed on 29 September, 2023.

  This is an initial public offering of American depositary shares, or ADSs, representing Class A ordinary shares of Adlai Nortye Ltd.  

Don't know how to trade IPO completion? Read Initial Public Offerings.
Overview of Adlai Nortye Ltd.
Health Care/Life Sciences • Pharmaceuticals
Adlai Nortye Ltd. operates as a clinical-stage biopharmaceutical company focused on the development of cancer therapies for patients with stages of tumors. It offers AN0025, a clinical stage, potential EP4 antagonist designed to modulate tumor microenvironment. The company was founded on May 9, 2018 and is headquartered in Hangzhou, China.
Market Cap
View Company Details